Clinical study of Cannabidiol in children and adolescents with Developmental and Epileptic Encephalopathy
Recruitment closed. Enrolment target met.
Primary Objective: This is a sequential, multi-stage, open-label, multi-national, multiple-center, multiple-dose study to assess the long-term safety and tolerability of ZYN002 in child and adolescent epilepsy patients 3 to <18 years of age having seizures associated with developmental and epileptic encephalopathies (DEE).
Principal Investigator: Lynette Sadlier
Study Coordinator: Natasha Eagle
Trial Website: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374807